Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(3 years from now) | |
US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Nov 5, 2022 |
Market Authorisation Date: 06 October, 2010
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene...
Dosage: AEROSOL, FOAM;TOPICAL
7
United States
4
Spain
4
Australia
4
European Union
2
Japan
2
Poland
2
Canada
2
New Zealand
1
Germany
1
Brazil
1
Portugal
1
Denmark
1
IB
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic